Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. Co. is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. Co.'s pipeline includes ARQ-255, ARQ-252, and ARQ-234. We show 23 historical shares outstanding datapoints in our ARQT shares outstanding history coverage, used to compute ARQT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ARQT market cap history over the course of time is important for investors
interested in comparing ARQT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ARQT versus a peer is one thing; comparing
ARQT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ARQT can fluctuate over the course of history.
With this page we aim to empower investors researching ARQT by allowing them to research the ARQT market cap history. |
Free ARQT Email Alerts:
Video: The Importance of Market Cap
